Analyst Consensus ?
ConsensusBuy29 ratings
Bullish1965.5%
Neutral1034.5%
Bearish00.0%
AMETEK, Inc. · AME · FY2025 Q1 · Calendar Q2 2025
AMETEK pairs resilient orders with tariff and margin watchpoints
The supplied analysis supports a constructive but conditional view: resilient orders, a near-record backlog, new products, and Paragon Medical recovery support the outlook, while tariffs, inventory destocking, and margin execution remain material tests.
Reported Before market openNYSEIndustrials
$57.68B market cap
70quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.69
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $1.74B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-1.4%
Event window
SPY move
+0.7%
Same window
Abnormal move
-2.1%
Stock minus SPY
Volume
1.1×
Versus trailing sessions
Subsequent drift
+6.9%
Up to 20 sessions
AMESPY benchmark
Ask FN2 about AME FY2025 Q1
Transcript, numbers and history already loaded
What drove AME's -1.4% move after FY2025 Q1 earnings?What changed in AME's guidance and outlook in FY2025 Q1?Give me the bull and bear case for AME after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The quarter's analysis emphasized strong orders, backlog, margin expansion, and Paragon Medical recovery, while adding quantified tariff exposure and localization as key considerations.
Guidance delta
Management reaffirmed full-year guidance; tariff mitigation was cited as supporting the reaffirmation.
Key takeaways
- Management described strong Q1 execution, with order growth, near-record backlog, margin expansion, and strong free-cash-flow conversion.
- Paragon Medical showed order and margin recovery, while new product launches and incremental R&D remain growth priorities.
- Tariffs and OEM inventory conditions remain the main near-term uncertainties despite maintained guidance.
Management priorities
- Launch EDAX Elite Ultra and Phantom KT-series products.
- Continue incremental R&D investment and pursue strategic acquisitions.
- Localize production further to mitigate tariff exposure.
Follow AME with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$251.67Previous close
$135Low
$236.93Average
$316High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Sep 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BNP Paribas | Outperform | Outperform | Maintain | Sep 11, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 6, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 6, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 5, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 5, 2026 |
| DA Davidson | Buy | Buy | Maintain | Aug 5, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 5, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Aug 5, 2026 |
| Baird | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 10, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | May 4, 2026 |
| Oppenheimer | Perform | Outperform | Downgrade | Jan 27, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jan 5, 2026 |
| B of A Securities | Buy | Neutral | Upgrade | Dec 16, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 2, 2023 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Feb 23, 2023 |
| Loop Capital | Buy | Buy | Maintain | Jul 19, 2022 |
| Rosenblatt | Buy | Buy | Maintain | Aug 4, 2021 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Mar 12, 2020 |
| Stephens & Co. | Overweight | Overweight | Maintain | Feb 7, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Oct 11, 2019 |
| Jefferies | Buy | Buy | Maintain | Oct 13, 2017 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Feb 15, 2017 |
| Stifel Nicolaus | Buy | Buy | Maintain | Aug 5, 2016 |
| Stifel | Buy | Buy | Maintain | Aug 5, 2016 |
| Deutsche Bank | Hold | Hold | Maintain | Jan 7, 2013 |
| UBS | Neutral | Neutral | Maintain | Oct 31, 2012 |
| Ladenburg Thalmann | Buy | Hold | Upgrade | Jul 24, 2012 |
| Langenberg & Company | Hold | Buy | Downgrade | Apr 27, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $251.67. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Vertical Research | Analyst unavailable | $255 | $237.72 | +1.3% | Sep 8, 2026 |
| Truist Financial | Analyst unavailable | $316 | $255.23 | +25.6% | Aug 6, 2026 |
| Seaport Global | Scott Graham | $290 | $255.81 | +15.2% | Aug 5, 2026 |
| RBC Capital | Deane Dray | $291 | $254.5 | +15.6% | Aug 5, 2026 |
| Robert W. Baird | Quinn Fredrickson | $275 | $254.05 | +9.3% | Aug 5, 2026 |
| KeyBanc | Analyst unavailable | $295 | $254.05 | +17.2% | Aug 5, 2026 |
| Morgan Stanley | Analyst unavailable | $245 | $234.99 | -2.7% | Jul 10, 2026 |
| Truist Financial | Jamie Cook | $303 | $237.13 | +20.4% | Jul 2, 2026 |
| Redburn Partners | Richard Radbourne | $265 | $231.27 | +5.3% | Jun 18, 2026 |
| Truist Financial | Analyst unavailable | $275 | $231.3 | +9.3% | May 4, 2026 |
| Barclays | Julian Mitchell | $230 | $230.48 | -8.6% | May 4, 2026 |
| Robert W. Baird | Quinn Fredrickson | $244 | $231.98 | -3.0% | May 1, 2026 |
| Mizuho Securities | Analyst unavailable | $270 | $232.62 | +7.3% | May 1, 2026 |
| BMO Capital | Daniel DiCicco | $253 | $211.47 | +0.5% | Mar 26, 2026 |
| Robert W. Baird | Analyst unavailable | $245 | $227.83 | -2.7% | Feb 5, 2026 |
| Truist Financial | Analyst unavailable | $265 | $229.46 | +5.3% | Feb 4, 2026 |
| RBC Capital | Analyst unavailable | $257 | $227.97 | +2.1% | Feb 4, 2026 |
| Mizuho Securities | Analyst unavailable | $235 | $228.92 | -6.6% | Feb 4, 2026 |
| Barclays | Julian Mitchell | $220 | $228.92 | -12.6% | Feb 4, 2026 |
| Deutsche Bank | Analyst unavailable | $271 | $213.14 | +7.7% | Jan 21, 2026 |
| Morgan Stanley | Christopher Snyder | $215 | $211.1 | -14.6% | Jan 12, 2026 |
| Barclays | Julian Mitchell | $210 | $214.16 | -16.6% | Jan 7, 2026 |
| KeyBanc | Analyst unavailable | $235 | $211.31 | -6.6% | Jan 6, 2026 |
| Melius Research | Rob Wertheimer | $235 | $212.09 | -6.6% | Jan 5, 2026 |
| Mizuho Securities | Analyst unavailable | $230 | $209.14 | -8.6% | Jan 5, 2026 |
| D.A. Davidson | Analyst unavailable | $240 | $199.92 | -4.6% | Dec 8, 2025 |
| Robert W. Baird | Richard Eastman | $204 | $202.11 | -18.9% | Nov 3, 2025 |
| Seaport Global | Analyst unavailable | $240 | $199.96 | -4.6% | Oct 31, 2025 |
| RBC Capital | Deane Dray | $229 | $198.84 | -9.0% | Oct 31, 2025 |
| KeyBanc | Analyst unavailable | $220 | $198.32 | -12.6% | Oct 31, 2025 |
| Barclays | Analyst unavailable | $205 | $198.32 | -18.5% | Oct 31, 2025 |
| Truist Financial | Jamie Cook | $229 | $181.42 | -9.0% | Oct 8, 2025 |
| Mizuho Securities | Brett Linzey | $212 | $182.75 | -15.8% | May 16, 2025 |
| Truist Financial | Jamie Cook | $219 | $166.92 | -13.0% | Oct 9, 2024 |
| Oppenheimer | Christopher Glynn | $190 | $163.9 | -24.5% | Sep 10, 2024 |
| Seaport Global | Scott Graham | $200 | $154 | -20.5% | Aug 2, 2024 |
| Truist Financial | Jamie Cook | $204 | $165.57 | -18.9% | Jul 2, 2024 |
| Oppenheimer | Christopher Glynn | $200 | $169.13 | -20.5% | May 22, 2024 |
| Seaport Global | Scott Graham | $208 | $168.06 | -17.4% | May 6, 2024 |
| Robert W. Baird | Richard Eastman | $171 | $166.56 | -32.1% | May 6, 2024 |
| RBC Capital | Deane Dray | $216 | $179.34 | -14.2% | Apr 4, 2024 |
| Truist Financial | Jamie Cook | $210 | $181.53 | -16.6% | Mar 13, 2024 |
| Morgan Stanley | Analyst unavailable | $152 | $142.36 | -39.6% | Jan 6, 2023 |
| Mizuho Securities | Brett Linzey | $140 | $129.31 | -44.4% | Aug 15, 2022 |
| Morgan Stanley | Analyst unavailable | $145 | $126.04 | -42.4% | Aug 3, 2022 |
| RBC Capital | Analyst unavailable | $135 | $125.85 | -46.4% | Aug 3, 2022 |
| Loop Capital Markets | Analyst unavailable | $155 | $109.1 | -38.4% | Jul 19, 2022 |
| Mizuho Securities | Analyst unavailable | $135 | $110.92 | -46.4% | Jul 18, 2022 |
| Morgan Stanley | Joshua Pokrzywinski | $135 | $121.86 | -46.4% | Jun 3, 2022 |
| Morgan Stanley | Analyst unavailable | $144 | $124.06 | -42.8% | May 4, 2022 |
| RBC Capital | Analyst unavailable | $148 | $124.31 | -41.2% | May 4, 2022 |
| KeyBanc | Steve Barger | $145 | $124.31 | -42.4% | May 4, 2022 |
| D.A. Davidson | Matt Summerville | $160 | $138.12 | -36.4% | Aug 3, 2021 |
Track every rating change on AME the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAMETEK, Inc. is a global enterprise that develops and markets a diverse portfolio of electronic instruments and electromechanical devices. The company's operations are structured into two principal divisions: the Electronic Instruments Group (EIG) and the Electromechanical Group (EMG). The EIG segment provides sophisticated instrumentation solutions catering to various sectors, including process control, aerospace, power generation, and general industrial applications. It also delivers specialized process and analytical tools essential for industries such as oil and gas, petrochemicals, pharmaceuticals, semiconductors, automation, and food and beverage production. Furthermore, EIG supplies equipment for laboratory settings, ultra-precision manufacturing, medical diagnostics, and critical test and measurement tasks.…
Historical context
All AME earningsIndustrials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| CTAS Cintas Corporation | FY2027 Q1 · Calendar Q3 2026 | +3.0% | -3.4% | Cintas raises FY2027 guidance as Q1 growth broadens |
| PAYX Paychex, Inc. | FY2027 Q1 · Calendar Q3 2026 | +1.5% | -8.8% | Paychex maintains FY27 outlook as PEO and AI momentum strengthen |
| FPS Forgent Power Solutions, Inc. | FY2026 Q4 · Calendar Q3 2026 | +4.3% | +9.5% | Forgent Power Solutions pairs record results with an aggressive FY27 buildout |
| CPRT Copart, Inc. | FY2026 Q4 · Calendar Q3 2026 | -8.7% | -2.6% | Copart pairs international growth with ACV investment amid higher costs |
| SUNB Sunbelt Rentals Holdings Inc | FY2027 Q1 · Calendar Q3 2026 | +19.2% | +5.9% | Sunbelt raises FY27 outlook as specialty rental demand accelerates |
| FRO Frontline Plc | FY2026 Q2 · Calendar Q3 2026 | +8.0% | +1.0% | Frontline posts a record quarter as tanker rates remain elevated |
Latest beats and misses
Who reports nextBeat on EPS
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
- SNXFY2026 Q3 · September 24, 2026+20.9% EPS-9.9% move
- DRIFY2027 Q1 · September 24, 20260.0% EPS-3.0% move
- CTASFY2027 Q1 · September 23, 2026+3.0% EPS-3.4% move
- PAYXFY2027 Q1 · September 23, 2026+1.5% EPS-8.8% move
- GISFY2027 Q1 · September 23, 2026+4.6% EPS+1.0% move
Get the AME recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-17T00:02:52.217204+00:00
- Polygon adjusted daily market bars · 2026-09-29T12:31:00.025749+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-29T12:31:00.023303+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-29. For educational purposes only; not investment advice.